A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
by on Tuesday, September 11th, 2012 | No Comments
Condition: B Cell Leukemia
Intervention: Biological: Autologous CD19 CAR+ EGFTt + T cells
Sponsors: Seattle Children’s Hospital; Seattle Children’s Hospital
Not yet recruiting – verified September 2012